ONCOLOGY RESEARCH

投稿咨询

官方网站：https://www.cognizantcommunication.com/journal-titles/oncology-research

投稿网址：orjournal@gmail.com

PMC链接：http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0965-0407%5BISSN%5D

肿瘤学研究致力于出版高质量、创新性的研究，重点是临床前、转化和临床癌症治疗的整个范围。感兴趣的具体领域包括开发新型小分子和靶向治疗的临床前和转化研究；药物敏感性机制；细胞药物抵抗机制；反应和/或抵抗的生物标志物；与癌症治疗相关的新型实验模型系统和技术；药物遗传学和药物基因组学；个性化医学；免疫治疗和临床免疫学；基因治疗；放射生物学和放射治疗的新方法。或与化疗结合使用。作为临床前癌症治疗焦点的一部分，该杂志还将重点放在药物设计、化学生物学和药物筛选方面的临床前研究。虽然该杂志的主要关注点是小分子和蛋白质药物，但也可以考虑其他分子实体。此外，欢迎提交研究草药/植物药在临床前和临床癌症治疗中的潜在作用的报告；但是，重要的是要证明这些药物具有高质量，并确认批次间的一致性。除了最初的同行评议的文章外，该杂志还欢迎及时评论和/或评论关注临床前、转化和/或临床癌症治疗的主题。

Oncology Research is committed to publishing high-quality, innovative research that is focused on the entire range of preclinical, translational, and clinical cancer therapeutics.Specific areas of interest include preclinical and translational research in development of novel small molecules and targeted therapies; mechanisms of drug sensitivity; mechanisms of cellular drug resistance; biomarkers of response and/or resistance; novel experimental model systems and technologies relating to cancer therapeutics;pharmacogenetics and pharmacogenomics; personalized medicine; immunotherapy and clinical immunology; gene therapy; and radiobiology and novel approaches to radiation therapy either alone or in combination with chemotherapy. As part of the preclinical cancer therapeutics focus, the journal also prioritizes preclinical studies that are focused on drug design, chemical biology, and drug screening. While the journal’s primary focus is on small molecules and protein drugs, other molecular entities may be considered. In addition, submissions that investigate the potential role of herbal/botanical medicines in preclinical and clinical cancer therapy are welcomed; however, it will be important to document that these medicines are of high quality, with confirmation of batch to batch consistency. In addition to original peer-reviewed articles, the journal also welcomes timely reviews and/or commentaries on topics that focus on preclinical, translational, and/or clinical cancer therapeutics.